Novozymes A/S – (NVZMY) Downgraded by Zacks Investment Research to “Hold”
Novozymes A/S – (NASDAQ:NVZMY) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “
Separately, Jefferies Group LLC set a $48.00 price objective on Novozymes A/S – and gave the company a “hold” rating in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $50.00.
Novozymes A/S – (NASDAQ NVZMY) opened at 50.91 on Wednesday. The company has a 50-day moving average of $48.79 and a 200 day moving average of $44.28. Novozymes A/S – has a one year low of $31.57 and a one year high of $51.42. The firm has a market cap of $15.03 billion and a P/E ratio of 31.35.
Novozymes A/S – (NASDAQ:NVZMY) last issued its quarterly earnings data on Friday, August 11th. The biotechnology company reported $0.36 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.39 by ($0.03). The business had revenue of $522.72 million during the quarter. Equities research analysts expect that Novozymes A/S – will post $1.71 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Novozymes A/S – (NVZMY) Downgraded by Zacks Investment Research to “Hold”” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/novozymes-as-nvzmy-downgraded-by-zacks-investment-research-to-hold/1574774.html.
Novozymes A/S – Company Profile
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.
Receive News & Ratings for Novozymes A/S - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S - and related companies with Analyst Ratings Network's FREE daily email newsletter.